Investing.com -- Valneva SE (NASDAQ:VALN) stock gained 3.7% on Thursday after the specialty vaccine company reported positive final Phase 2 antibody persistence and safety results for its chikungunya ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback